We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Share this :
Print
Cell Signaling Phospho-Bcl9l (Ser915) Antibody
Cell Signaling Phospho-Bcl9l (Ser915) Antibody - CSIG (Additional S&H or Hazmat Fees May Apply)
List Price
$353.00
Your Price
$353.00
HOW MUCH YOU SAVE:
0.00 %
NETA PART: | CSIG-13325S |
MFG.PART: | 13325S |
UNSPSC: | 41116111 |
Manufacturer: | Cell Signaling |
Size | 100 µl |
Reactivity | H |
Sensitivity | Endogenous |
Molecular Weight (kDa) | 200 |
Source/Isotype | Rabbit |
Application/Dilution | {Western Blotting: 1:1000} |
Storage | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody. |
Specificity/Sensitivity | Phospho-BCL9L (Ser915) Antibody recognizes endogenous levels of BCL9L protein only when phosphorylated at Ser915. |
Species Reactivity | Human |
Source/Purification | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser915 of human BCL9L protein. Antibodies are purified by protein A and peptide affinity chromatography. |
Background | B-cell CLL/lymphoma 9-like protein (BCL9L, BL2, Bcl9-2, DLNB11) is a transcriptional activator that was originally identified in silico based on homology to BCL9 (1). BCL9L was subsequently found to play an important role in Wnt/β-catenin signaling by interacting with β-catenin and enhancing the transactivation potential of the β-catenin/TCF complex (2). Research studies show that BCL9L can increase the tumorigenic effect of aberrant Wnt signaling in some cases of colorectal cancer (2). Expression of BCL9L is correlated with tumor progression in colorectal (3) and breast cancer (4). Targeted deletion of BCL9 and BCL9L in the intestinal epithelium resulted in abrogation of Wnt target genes, including those controlling epithelial-mesenchymal transition and stem-cell like properties (5).Phospho-BCL9L (Ser915) Antibody is directed at a site that was identified at Cell Signaling Technology (CST) using PhosphoScan®, CSTs LC-MS/MS platform for modification site discovery. Phosphorylation at Ser915 was discovered using an AMPK substrate antibody. Please visit PhosphoSitePlus®, CSTs modification site knowledgebase, at www.phosphosite.org for more information. |
SKU | CSIG-13325S |
---|---|
Supplier Part Number | 13325S |
UM | UNIT |
UNSPSC | 41116111 |
Manufacturer | Cell Signaling |
MSDS URL | https://www.cellsignal.com/contents/technical/safety-data-sheet-(sds)/resources-safety-data-sheets |
Temperature | -20C |
ProductLine | CSIG |
Qty | 1 |
MinOrderQty | 1 |
Weight | 7.00 |
Lead Time | 5 Business Days |
Hazardous | N |